ClinicalTrials.gg
CompletedNCT03325010Updated Jun 28, 2021Results posted

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

A Phase 2 interventional study of Valbenazine and Placebo oral capsule in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 35 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-28.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
19th of 105
127 · median 33
Started
2017
with 4 others
Phase 2
26 of 139
4 open now
Registered
81st of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 19th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2017, is one of 26 in phase 2, and was the 81st registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of Tourette Syndrome (TS)
  2. Have at least moderate tic severity
  3. Have TS symptoms that impair school, occupational, and/or social function
  4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  5. Be in good general health
  6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen
  7. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening
  2. Have a known history of long syndrome or cardiac arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to VMAT2 inhibitors
  6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening
  7. Have a known history of substance dependence, substance (drug) or alcohol abuse
  8. Have a significant risk of suicidal or violent behavior
  9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study
  10. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo (matching valbenazine) once daily for 12 weeks.

    Drug: Placebo oral capsule

  • Experimental
    Valbenazine

    Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects \<50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.

    Drug: Valbenazine

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: Ingrezza, NBI-98854

  • DrugPlacebo oral capsule

    non-active dosage form

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

    The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score

    The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

    Time frame: Baseline, Week 12

  2. Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12

    A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.

    Time frame: Baseline, Week 12

  3. Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12

    The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. A CGI-TS-Improvement responder is defined, on a per-visit basis, as a participant whose CGI-TS-Improvement score is 1 ("Very much improved") or 2 ("Much improved") at the specified postbaseline visit.

    Time frame: Week 12

07

Results

Posted Jun 28, 2021

Participant flow

This study enrolled male and female pediatric participants, 6 to 17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or -V) diagnosis of Tourette Syndrome (TS) in the United States. The first and last participants were enrolled on 05 October 2017 and 19 July 2018, respectively.

Participant flow — Overall Study
MilestonePlaceboValbenazine
Started6463
Safety analysis set6259
Full analysis set6158
Completed5543
Not completed920
Withdrew: Adverse event38
Withdrew: Protocol violation18
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up10
Withdrew: Physician decision11
Withdrew: Lack of efficacy20

Outcome measures

PrimaryChange From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
score on a scalePlaceboValbenazine
Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)-6.8 ± 1.0-8.9 ± 1.1
Statistical analysis
  • Placebo vs Valbenazine · Mixed Models Analysis · p = 0.1768 (Nominal p-value is considered statistically significant if less than 0.05. To control for multiplicity, comparisons were tested sequentially.) · Mean difference (net): -2.1 · 95% CI -5.2 to 1.0
SecondaryChange From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score

The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score
Score on scalePlaceboValbenazine
Change From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score-0.7 ± 0.1-1.0 ± 0.1
Statistical analysis
  • Placebo vs Valbenazine · Mixed Models Analysis · p = 0.1095 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value for this outcome measure would only be evaluated for statistical significance if the primary outcome measure was statistically significant.) · Mean difference (net): -0.3 · 95% CI -0.6 to 0.1
SecondaryParticipants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12

A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.

Time frame:
Baseline, Week 12
Reported as:
Count of participants · Participants
Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12
ParticipantsPlaceboValbenazine
Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 122118
Statistical analysis
  • Placebo vs Valbenazine · Cochran-Mantel-Haenszel · p = 0.8190 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value for this outcome measure would only be evaluated for statistical significance if the primary and preceding secondary outcome measures were statistically significant.) · Risk difference (rd): 3.0Stratified by baseline weight group (\<50 kg, ≥50 kg).
SecondaryParticipants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12

The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. A CGI-TS-Improvement responder is defined, on a per-visit basis, as a participant whose CGI-TS-Improvement score is 1 ("Very much improved") or 2 ("Much improved") at the specified postbaseline visit.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12
ParticipantsPlaceboValbenazine
Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 121224
Statistical analysis
  • Placebo vs Valbenazine · Cochran-Mantel-Haenszel · p = 0.0008 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value for this outcome measure would only be evaluated for statistical significance if the primary and preceding secondary outcome measures were statistically significant.) · Risk difference (rd): 33.6Stratified by baseline weight group (\<50 kg, ≥50 kg)

Adverse events

Collected over Up to 14 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/62 (0%)1/62 (1.6%)17/62 (27.4%)
Valbenazine0/59 (0%)0/59 (0%)32/59 (54.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboValbenazine
RashSkin and subcutaneous tissue disorders1/620/59
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboValbenazine
HeadacheNervous system disorders5/6211/59
SomnolenceNervous system disorders0/6211/59
VomitingGastrointestinal disorders4/626/59
FatigueGeneral disorders5/626/59
Suicidal ideationPsychiatric disorders1/625/59
Abdominal pain upperGastrointestinal disorders2/623/59
Gastrooesophageal reflux diseaseGastrointestinal disorders0/623/59
NauseaGastrointestinal disorders2/623/59
IrritabilityGeneral disorders2/623/59
InfluenzaInfections and infestations1/623/59

Baseline characteristics

Full analysis set, which includes all randomized participants who have at least one evaluable change from baseline value for Total Tic Score reported at a visit (either scheduled or mapped early termination visit) during the treatment period.

Age, Continuous
Age, Continuous(Years)PlaceboValbenazineTotal
Mean12.4 ± 2.612.2 ± 2.712.3 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboValbenazineTotal
Female91019
Male5248100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboValbenazineTotal
Hispanic or Latino151429
Not Hispanic or Latino464490
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboValbenazineTotal
Race — American Indian or Alaska Native000
Race — Asian314
Race — Black or African American819
Race — White4953102
Race — Native Hawaiian or Other Pacific Islander101
Race — Other011
Race — Multiple022
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)(score on scale)PlaceboValbenazineTotal
Mean31.2 ± 9.029.3 ± 8.730.3 ± 8.9
08

Study locations

35 sites
  • Neurocrine Clinical Site
    Sun City, Arizona 85351, United States
  • Neurocrine Clinical Site
    Rogers, Arkansas 72758, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    San Diego, California 92108, United States
  • Neurocrine Clinical Site
    Santa Clarita, California 91321, United States
  • Neurocrine Clinical Site
    New Haven, Connecticut 06519, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33018, United States
  • Neurocrine Clinical Site
    Loxahatchee Groves, Florida 33470, United States
  • Neurocrine Clinical Site
    Orange City, Florida 32763, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32801, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
  • Neurocrine Clinical Site
    Tampa, Florida 33609, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60634, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60637, United States
  • Neurocrine Clinical Site
    Naperville, Illinois 60563, United States
  • Neurocrine Clinical Site
    Iowa City, Iowa 52242, United States
  • Neurocrine Clinical Site
    Leawood, Kansas 66206, United States
  • Neurocrine Clinical Site
    Boston, Massachusetts 02114, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Nashua, New Hampshire 03060, United States
  • Neurocrine Clinical Site
    Mount Arlington, New Jersey 07856, United States
  • Neurocrine Clinical Site
    Voorhees, New Jersey 08043, United States
  • Neurocrine Clinical Site
    Bronx, New York 10467, United States
  • Neurocrine Clinical Site
    New York, New York 10036, United States
  • Neurocrine Clinical Site
    Durham, North Carolina 27705, United States
  • Neurocrine Clinical Site
    Memphis, Tennessee 38119, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75243, United States
  • Neurocrine Clinical Site
    Houston, Texas 77058, United States
  • Neurocrine Clinical Site
    Irving, Texas 75062, United States
  • Neurocrine Clinical Site
    Everett, Washington 98201, United States
  • Neurocrine Clinical Site
    Seattle, Washington 98105, United States
  • Neurocrine Clinical Site
    Spokane, Washington 99204, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2018, 12 months.

Results were first posted in Jun 2021, 2 years 7 months after primary completion. A results delay was requested in Mar 2019.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Oct 30, 2017
StartActual
Oct 5, 2017
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 16, 2018
Results delay requested
Mar 11, 2019
Results first posted
Jun 28, 2021
Last update
Jun 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03325010
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Oct 5, 2017
Primary completion
Nov 1, 2018
Completion
Nov 16, 2018
Results posted
Jun 28, 2021
Last update
Jun 28, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion